

Special Issue

Host Innate Immune Responses against SARS-CoV-2

Message from the Guest Editor

Most often, the morbidity and mortality associated with SAR-CoV-2 infection are due to the collateral damage caused by exaggerated and unabated immune response (“cytokine storm”) mounted by the host to protect against the infection. The induction of a cytokine storm is the root cause of pathogenic inflammation in SARS-CoV-2-infected patients. For those whom were critically ill or have died from SARS-CoV-2 infection, severe clinical manifestations did not develop in the early stages of the disease. In fact, these patients deteriorated suddenly in the later stages of the disease or in the process of recovery, rapidly succumbing to ARDS/acute lung injury and multiple-organ failure, resulting in death within a short time. Cytokine storm is considered to be one of the major causes of ARDS and multiple-organ failure and plays an important role in the process of disease aggravation. This Special Issue of *Vaccines* will cover all of these topics relevant to understanding host innate immune responses against SARS-CoV-2.

Guest Editor

Dr. Adi Idris

Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia

Deadline for manuscript submissions

closed (31 March 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/80287

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).